Background: The substance P/neurokinin 1 receptor pathway is critical in chronic pruritus; anecdotal evidence suggests that antagonism of this pathway can reduce chronic itch.
Results: Serlopitant treatment resulted in a dose-dependent decrease in pruritus. The mean percentage decreases from baseline visual analog scale pruritus scores were statistically significantly larger with the 1-and 5-mg doses of serlopitant (P = .022 and P = .013, respectively) than with placebo at week 6. No significant safety or tolerability differences were detected among the groups.
Limitations: The sample size was insufficient for subgroup analyses of the efficacy of serlopitant for chronic pruritus on the basis of underlying conditions.
Conclusions: Serlopitant, 1 mg and 5 mg daily, was associated with a statistically significant reduction in chronic pruritus and was well tolerated (NCT01951274). ( J Am Acad Dermatol 2018;78:882-91.)
Key words: chronic pruritus; itch; neurokinin 1 receptor; NK1 receptor; NK1 receptor antagonist; serlopitant; substance P.
Pruritus is a prevalent and debilitating symptom of a number of dermatologic, neurologic, systemic, and psychiatric disorders, 1 including atopic dermatitis, psoriasis, and kidney disease. [1] [2] [3] Chronic pruritus may result in sleeplessness, inability to work, aggression, anxiety, depression, and low quality of life. 1, 4, 5 Symptomatic relief of pruritus is uniformly elusive. There are no drugs approved specifically for the treatment of chronic pruritus, and the therapies used often have limited efficacy and can be associated with significant side effects. Thus, patients often experience severe long-lasting pruritus without improvement, intensifying the negative impact on quality of life and psychosomatic reactions. 1, 6 Over the past decade, our understanding of neural and cellular circuitries involved in pruritus has significantly expanded. 6, 7 The tachykinin substance P (SP) and its receptor, neurokinin 1 receptor (NK 1 R), are well established as a pivotal pathway in histamine-independent pruritus. 8, 9 Multiple case reports suggest that patients with chronic pruritus respond to treatment with aprepitant, [10] [11] [12] [13] [14] the first approved NK 1 R antagonist. However, aprepitant is indicated only for use in chemotherapy-induced nausea and vomiting (treatment courses are limited to 3-day cycles), and its use is restricted by the potential for significant metabolic drug interactions and its nonlinear pharmacokinetic profile. 15, 16 Serlopitant is an NK 1 R antagonist that was originally developed for chronic use for the treatment of overactive bladder, and in a phase 2 trial it was found to be generally well tolerated. 17 On the basis of our evolving understanding of the role of the NK 1 R in pruritus, 6 ,7 studies demonstrating a reduction in pruritus with NK 1 R inhibition, [10] [11] [12] [13] [14] and the serlopitant safety data, 17 a clinical study was conducted to assess the efficacy of serlopitant for the treatment of chronic pruritus. Here, we report results from the phase 2, multicenter clinical trial of serlopitant for chronic pruritus.
METHODS Study design and patients
A total of 25 US centers (listed in the Supplemental Table I ; available at http://www.jaad.org) participated in this randomized, double-blind, 6-week, placebo-controlled study (NCT01951274) investigating the safety and efficacy of 3 different doses of serlopitant versus placebo for severe chronic pruritus. Patients aged 18 to 65 years who were in good health and had pruritus for 6 weeks or more that was unresponsive to treatment with current therapies such as antihistamines or topical steroids (considered first-line therapies for pruritus 18 ) and a score of 7 cm or higher on the visual analog scale (VAS) for pruritus at baseline were eligible. Patients with serum creatinine, aspartate aminotransferase, or alanine aminotransferase levels higher than twice
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the upper limit of normal were excluded. Thus, enrollment of patients with uremic 19 or cholestatic 20 pruritus was minimized to reduce possible confounding effects from these specific comorbidities.
Patients with pruritus of neuropathic or psychogenic etiology or drug-induced pruritus were also excluded.
The study protocol was approved by the institutional review board overseeing each site (approval number, 28493; date, August 29, 2013 ). All patients were required to give their written informed consent in accordance with Good Clinical Practice and the local regulatory requirements.
Randomization and masking
Almac Group, Inc (Craigavon, UK) was responsible for patient randomization and material logistics. An interactive web-based response system was used to randomly assign study patients in a 1:1:1:1 ratio to receive serlopitant, 0.25, 1, or 5 mg, or placebo (Fig 1) (for additional details, see the Supplemental Data; available at: http://www.jaad.org).
Procedures
After a 2-week washout period, patients received a loading dose of 3 tablets at baseline (day 1), Physicians completed a Physician's Global Assessment (PGA) survey with an 11-point scale measuring change from baseline. The PGA asks physicians to rate the change in lesions (if any) from plus 5 (markedly improved) to minus 5 (markedly worse). Follow-up assessment was performed 4 weeks after treatment (week 10). Dose selection and pharmacokinetic methodology are described in the Supplemental Data.
Outcomes
The primary efficacy end point was the percentage change in VAS pruritus scores from baseline, comparing serlopitant to placebo by using patients' reports of pruritus intensity. Secondary efficacy end points included the NRS pruritus score and total score and domains of the DLQI, the PSSQ-I, the SGA, and the PGA. Safety was assessed through the monitoring of adverse or serious adverse events, laboratory assessments, vital signs, electrocardiograms, serum levels of serlopitant, and abbreviated physical examinations.
Statistical analysis
VAS pruritus score was reported in an e-diary twice per day. Baseline for VAS was the average of 2 days of measurements before study drug administration. The baseline for all measurements other than the VAS was the last measurement before administration of the study drug. For analysis of VAS reduction, the average of 2 daily measurements was used to create daily measures that were combined to make weekly measures. Intention-to-treat principles were used for the primary analyses of efficacy for all randomized patients (N = 257). The statistical analysis was prepared by using a repeated measures linear mixed-effects model. Pairwise estimates of differences between each serlopitant dose and placebo, associated confidence intervals, and P values were computed by using SAS software (version 9.1 or higher, SAS Institute, Inc, Cary, NC) for each pairwise comparison of serlopitant dose versus placebo. P values of .05 or less were regarded as statistically significant. No multiplicity adjustments were used. Missing data were not imputed. See the Supplemental Data for additional details.
RESULTS
From October 1, 2013, to December 2, 2014, a total of 368 patients were screened; 111 were not randomized because of screen failure, and 257 were randomized to receive placebo (n = 64) or serlopitant, 0.25 mg (n = 64), 1 mg (n = 65), or 5 mg (n = 64). Of those 257 patients, 222 (86.4%) completed the study (Fig 1) . Treatments were discontinued for 9 (14.1%), 7 (10.9%), 9 (13.8%), and 10 (15.6%) patients from the 4 arms, respectively. Reasons for discontinuation included adverse events, loss to follow-up, protocol violation, voluntary withdrawal, or other. Those enrolled in the study had a mean age of 43.7 years; 156 (60.7%) were female, and 167 (65.0%) self-identified as white (Table I) . Study groups were balanced for age, sex, race, ethnicity, = change from baseline in numeric rating scale (NRS) pruritus score (B). Data shown are estimates of the pairwise difference of least squares means and were generated by using a mixed-model analysis of covariance test with significance set at .05 level. One patient from the placebo group (20-004), 2 from the serlopitant 1-mg group (04-003 and 12-010), and 1 from the serlopitant 5-mg group (12-014), although part of the intention-to-treat population, were removed from the analysis. Patient 20-004 was randomized in error and did not receive study medication, patient 04-003 did not receive an e-diary during screening and had no baseline data, and patients 12-010 and 12-014 did not complete any e-diary information after screening. LS, least squares means; SE, standard error. Table IV ; available at http//:www.jaad.org). Most reported adverse events were mild or moderate; no treatmentrelated serious adverse events were reported (Table II) . No evidence of clinically meaningful trends in laboratory abnormalities or changes in vital signs was detected. Treatment-related adverse events occurred in 9.5% of patients (n = 6) in the placebo group and in 10.9% (n = 7), 13.8% (n = 9), and 12.5% (n = 8) of patients in the serlopitant 0.25-mg, serlopitant 1-mg, and serlopitant 5-mg groups, respectively. Adverse events accounted for 6 premature discontinuations (2 each in the placebo and serlopitant 5-mg groups and 1 each in the serlopitant 0.25-mg and serlopitant 1-mg groups) out of 35 total discontinuations. Of the patients who discontinued participation in the study, 2 had events considered unrelated to study treatment and 4 had events considered to be possibly or probably treatment related (headache and hypoesthesia [n = 1], diarrhea [n = 1], diarrhea and gastrointestinal pain [n = 1], and panic attack [n = 1]). A seventh discontinuation was recorded for a patient found to have a pre-existing condition (hypothyroidism) at the baseline/randomization study visit before administration of the study medication and therefore was not included in the patient count for treatment.
At week 6, the mean percentage decreases from baseline in VAS pruritus score were statistically significantly greater in the serlopitant 1-mg (P = .022) and serlopitant 5-mg (P = .013) dose groups versus in the placebo group (Fig 2, A and Table III) . A statistically significant difference from placebo emerged as early as week 3 of the study (1-mg dose, P = .042) (Fig 2, A and Supplemental Table V ; available at http//:www.jaad.org). At week 6, 43%, 38%, and 53% of patients in the serlopitant 0.25-mg, serlopitant 1-mg, and serlopitant 5-mg dose groups, respectively, reported a 4-cm decrease in average VAS pruritus score versus only 26% of placebo-treated patients (Fig 3, A) . The statistically significant difference in improvement of VAS pruritus scores between serlopitant and placebo remained through the follow-up visit 4 weeks after completion of study treatment (Supplemental Table V ).
The mean percentage changes from baseline in NRS pruritus score (Fig 2, B and Supplemental Table VI ; available at http//:www.jaad.org) showed larger decreases from baseline in the active treatment groups compared with the placebo group at weeks 1 through 6; these differences were statistically significant for the serlopitant 1-mg and serlopitant 5-mg groups at weeks 4, 5, and 6. At week 6, 46% of patients in the serlopitant 5-mg dose group reported a 4-point decrease in average NRS pruritus score versus 23% of patients who received placebo (Fig 3, B) .
A prespecified subgroup analysis of patients with a history of atopic diathesis (ie, atopic dermatitis, allergy, and/or asthma) revealed that serlopitant provided a greater reduction in pruritus, as measured by both VAS and NRS pruritus scores, compared with placebo at weeks 1 through 6 and week 10 (data not shown), with statistically significantly greater reductions in pruritus observed with serlopitant, 5 mg, at weeks 4, 5, and 6 (P\.05). These results were similar to those for the overall study population.
The mean overall DLQI score and mean individual domain scores decreased (indicating improvement) throughout the study in all treatment groups (Supplemental Table VII ; available at http//:www. jaad.org). The mean overall DLQI score was lower in the active treatment groups than in the placebo group at weeks 1 through 6 and week 10. Statistically significant improvements were observed in the overall DLQI score at week 4 for the serlopitant 1-mg group and in the active treatment groups for some individual DLQI domains.
As assessed by the SGA, pruritus improved from baseline in all treatment groups. The differences in the distribution of SGA ratings of pruritus severity relative to the placebo group, although not statistically significant, favored therapy (data not shown).
Results of the PSSQ-I questionnaire at week 6 indicated that approximately 50% fewer patients in the active arms than in the placebo arm met the criteria for having insomnia ( Supplemental Fig 1; available at http//:www.jaad.org). The percentages of patients who had insomnia decreased from baseline in every treatment group. At week 6, the differences relative to placebo were statistically significant for serlopitant, 1 mg, (sleep symptom criteria, daytime impairment criteria, and overallinsomnia disorder) and serlopitant, 5 mg, (sleep symptom criteria).
PGA scores for all serlopitant treatment groups (n = 170) at the week 6 visit indicated that 44.1% of patients ''improved'' and 9.4% became ''worse'' compared with 44.6% and 14.3%, respectively, for the placebo group. Of those who improved, 15.3% of serlopitant-treated patients were markedly improved or largely improved compared with 3.6% of placebotreated patients.
The results presented here are based on the intention-to-treat population and therefore include all enrolled individuals.
DISCUSSION
Serlopitant was well tolerated and provided a significant antipruritic effect in patients with severe chronic pruritus arising from a broad variety of etiologies that was refractory to anthistamines and corticosteroids. Results of the present study support the hypothesis that interrupting pruritus signaling by inhibiting the NK 1 R attenuates chronic pruritus derived from multiple primary causes. 10 Approximately 45% of patients presented with a dermatologic diagnosis; however, a similar percentage had received no dermatologic diagnosis to explain their long-standing symptoms. Nondermatologic causes were possible, but classification of patients was not required.
Efficacy outcomes were similar across multiple measures of pruritus, as well as in the prespecified subgroup analysis of patients with a history of atopic diathesis. Statistically significant differences from baseline VAS pruritus scores were observed as early as week 3 of treatment and remained 4 weeks following completion of study treatment, with no rebound in pruritus observed. The largest reduction in pruritus scores consistently occurred in the serlopitant 1-and serlopitant 5-mg groups.
Responder analysis using a 4-cm VAS reduction threshold demonstrated that a substantial portion of patients experienced a clinically relevant improvement in symptoms during treatment with serlopitant. The minimal important difference for clinical improvement of chronic pruritus ranks between a drop of 2 to 3 cm on the VAS or 2 to 3 points on the NRS, as demonstrated in a recent psychometric study. 23, 24 In fact, a score reduction of at least 4 cm or at least 4 points was recorded at the 5-mg serlopitant dose for more than 50% of the patients scored by VAS and nearly 50% of those scored by the NRS, respectively.
The 25% reduction from baseline in VAS pruritus score in the placebo group is in line with the average 24% placebo response per a meta-analysis of multiple clinical trials involving patients with chronic pruritus. 25 Although only the serlopitant 1-mg group showed a statistically significant difference from the placebo group in overall DLQI score, a number of individual domain scores did demonstrate statistically significant differences. Several factors may potentially influence the overall DLQI scores. The DLQI is widely used for the evaluation of quality of life in patients with pruritic conditions; however, concerns have been raised regarding the lack of unidimensionality and item bias based on age, sex, and nationality. [26] [27] [28] Whether this affected results from this study has not been determined. The incidence of insomnia was reduced by more than 50% in the serlopitant 1-and serlopitant 5-mg treatment arms at 6 weeks on the basis of responses to the PSSQ-I questionnaire, indicating significant symptomatic relief (Supplemental Fig 1) . The PGA did not show a statistically significant effect at week 6; however, skin lesions were not required for inclusion and not all patients had skin lesions at study entry.
Serlopitant was well tolerated; the most common treatment-emergent adverse events in the activetreatment groups were somnolence and diarrhea. The present study affirmed the safety profile of serlopitant; additionally, its safety is supported by data from multiple phase 1 (unpublished) and phase 2 trials that enrolled more than 1000 patients, some of whom took serlopitant for up to 1 year. 17 Because of the complex and multifactorial nature of pruritus pathogenesis, treatment of pruritus, especially severe and/or chronic pruritus, can be challenging. 1, 29, 30 Many of the currently available therapies used for chronic pruritus have limited efficacy, and some have significant side effects. 1, 31 Therefore, there is a significant unmet need for a safe, effective treatment for chronic pruritus.
In conclusion, serlopitant, a novel, potent, oral NK 1 R antagonist, was well tolerated and demonstrated positive results in the treatment of severe chronic pruritus in this multicenter, placebocontrolled, double-blind, randomized clinical trial. Additional studies of serlopitant for the treatment of pruritus are currently underway.
SUPPLEMENTAL DATA: METHODS

Randomization and masking
Randomization was performed by using the Almac Group, Inc (Craigavon, UK) validated interactive web-based response system IXRS, which automates the random assignment of treatment groups to bottle numbers that are blinded to investigators and patients by encoding (Almac Clinical Technologies, Souderton, PA). Treatment assignment was concealed from the patients, the investigators and their staff, and the clinical research team. The placebo tablets were formulated to be indistinguishable from serlopitant tablets (Almac, Craigavon, UK).
Procedures
Patients using stable doses of midpotency topical steroids at screening could continue their use during the study, and they could also continue the use of lotions. Dose selection was based on an unpublished phase 1 Merck study measuring brain neurokinin 1 receptor occupancy of serlopitant. Positron emission tomography quantified neurokinin 1 receptor blockade by serlopitant using a tracer molecule, 18 [F]SPA-RQ. After 14 days of dosing in healthy young men, a 5-mg dose of serlopitant achieved more than 94% brain receptor occupancy. Although the dosing required to suppress pruritic activity is unknown, the expected brain receptor occupancy for the 0.25-mg and 1-mg doses are 46% and 75%, respectively. Loading dose was administered at the study site. In the present study, a pharmacokinetic analysis was conducted at 4 weeks to analyze blood serum levels.
In the Pittsburgh Sleep Symptom QuestionnaireInsomnia (PSSQ-I), sleep disorders were characterized in terms of sleep symptom criteria, duration criteria, daytime impairment criteria, and overall insomnia disorder. The Physician's Global Assessment survey provided a measure of skin condition in the pruritic area(s). The investigators were instructed to record no change from baseline at postbaseline assessments for patients who had no visibly affected skin at baseline, as skin cannot improve from normal-appearing/not affected. Any worsening of the skin condition would be recorded as a negative change.
Statistical analysis
The sample size was based on a 2-sided alpha level of 5% and 80% power, a 10% dropout rate, a mean percent reduction of 50% for serlopitant versus 30% for placebo, and a standard deviation of 35.5. Sample size estimates were based on published data from an open-label study using aprepitant.
S1
All statistical analyses were conducted with SAS software (version 9.1 or higher, SAS Institute Inc, Cary, NC).
Primary efficacy
The primary efficacy variable, pruritus severity as measured on a visual analog scale (VAS), was recorded twice daily in an electronic diary. These measures were combined to make daily and weekly measures by averaging the available results on the given study days and study weeks. The weekly measures were used to create the primary percentage change from baseline end point. The statistical analysis of the primary efficacy VAS end point was prepared by using a repeated measures linear mixed-effects model ''mixed model.'' A cell means parameterization, with a parameter for each combination of dose and week, and a random effect for patient was used. Estimates of treatment effect on VAS were prepared by using pairwise estimates of differences (difference of least square means) between each dose and placebo at each study week. Confidence intervals and P values for each pairwise 2-sided comparison of serlopitant dose versus placebo for each week were produced. The primary time point of interest was week 6. Multiplicity adjustments for the multiple treatment groups and time points were not performed. Missing data were not imputed.
Secondary efficacy
Secondary efficacy end points included the severity of pruritus as rated by the 11-point numeric rating scale, the Dermatology Life Quality Index score, the PSSQ-I, the Subject's Global Assessment, and the Physician's Global Assessment. The Numeric Rating Scale data were treated as continuous, and a statistical analysis was prepared by using a linear mixed-effects model (defined as model I), as described for the primary efficacy analysis. The Dermatology Life Quality Index domains were expressed as a percentage defined in the scoring instructions. S2 The data were treated as continuous, and the analysis of the overall score was prepared by using a linear mixed-effects model (similar to model I). The PSSQ-I was scored according to the developer's instructions, and the data were summarized by percentage of subjects with insomnia disorder.
RESULTS
A pharmacokinetic anomaly in which a number of patients in the serlopitant treatment groups had no detectable levels of serlopitant in their blood samples was identified.
A comprehensive, independent audit was conducted; it included a review of compliance at multiple study sites, study conduct, statistical programming, monitoring, data management, and other procedures. The audit determined that the pharmacokinetic issue was limited to a single site and confirmed that there were no systemic compliance issues in the study. Minor statistical programming errors were identified and corrected. The independent auditor confirmed the initial efficacy and safety findings of the study. The significance and study outcomes are consistent regardless of whether the patients from this clinical site were included or excluded from the overall study population. Data are expressed as n (%). Concomitant medications are defined as medications having stop dates on or after the start of study medication.
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Supplemental The VAS from the e-diary was recorded in millimeters. One patient from the placebo group (20-004), 2 from the serlopitant 1-mg group (04-003 and 12-010), and 1 from the serlopitant 5-mg group (12-014), although part of the ITT population were removed from the analysis. Patient 20-004 was randomized in error and did not receive study medication, patient 04-003 did not receive an e-diary during screening and had no baseline data, and patients 12-010 and 12-014 did not complete any e-diary information after screening. CI, Confidence interval; e-diary, electronic diary; ITT, intention-to-treat; LS, least squares; VAS, visual analog scale. *Model 1 included a parameter for each combination of dose and week and a random effect for patient. y Placebo group is the reference. NRS baseline is defined as the last measurement before day 1. One patient from the placebo group (20-004), 2 from the serlopitant 1-mg group (04-003 and 12-010), and 1 from the serlopitant 5-mg group (12-014), although part of the ITT population were removed from the analysis. Patient 20-004 was randomized in error and did not receive study medication, patient 04-003 did not receive an e-diary during screening and had no baseline data, and patients 12-010 and 12-014 did not complete any e-diary information after screening. CI, Confidence interval; e-diary, electronic diary; ITT, intention-to-treat; LS, least-squares; NRS, numeric rating scale. *Model 1 included a parameter for each combination of dose and week and a random effect for patient. y Placebo group is the reference. CI, Confidence interval; DLQI, Dermatology Life Quality Index; ITT, intention-to-treat; LS, least squares. *Model 1 included a parameter for each combination of dose and week and a random effect for patient. y Placebo group is the reference.
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